We are pleased to announce that Dr. Amedeo Lonardo has been appointed Editor-in-Chief of Metabolites (ISSN: 2218-1989).

He graduated in medicine and is a specialist in gastroenterology and digestive endoscopy, pediatrics, and internal medicine. In 2017, he qualified as a full professor of gastroenterology and an associate professor of internal medicine following the Italian University National Examination.

As an expert reviewer, Dr. Lonardo has worked for innumerable high-ranking medical journals and has completed 1,124 peer reviews (May 2024). He has also been recognized as a Highly Cited Researcher (2018-2023; Cross-Field; Biology and Biochemistry; Clinical Medicine; Pharmacology and Toxicology; Multidisciplinary; Biology and Biochemistry).

He has authored/co-authored 247 published papers, achieving an h-index of 74 with 21,306 citations (Google Scholar accessed in May 2024), and has served as a lecturer at national/international and local congresses and seminars. He has also participated in Italian and European scientific projects and is an Editorial Board Member of various medical journals.

After working for 35 years as a hospital physician, a tutor for medical graduates specializing in internal medicine, and a professor of internal medicine (School of Specialization of Allergology and Clinical Immunology) in the Medical School of the University of Modena and Reggio Emilia, Dr. Lonardo is now fully occupied by his editorial interests. These comprise the history of medicine, MASLD, metabolic syndrome, and precision/sex medicine.

The following is a short Q&A with Dr. Amedeo Lonardo, who shared his vision for the journal with us, as well as his views on the research area:

1. What appealed to you about the journal that made you want to take on the role of Editor-in-Chief?
I felt honored and flattered by the invitation I received to serve as the Editor-in-Chief of this journal, for which I had previously served as a Section Editor-in-Chief. I am fascinated by the mechanisms underlying the publication of scientific discoveries in general, and Metabolites is a well-established and prestigious journal with great potential for progress.

2. What is your vision for the journal?
Based on my specific editorial expertise and scientific interests, I am committed to offering Metabolites fair and transparent peer reviews and will guarantee that the papers accepted for publication have the potential to be cited by other scientists globally. In my vision, it is important to try to reposition Metabolites in the field of clinically relevant topics, including metabolic disorders, while maintaining the traditional scope of the journal.

3. What does the future of this field of research look like?
Metabolic disorders are a leading health issue globally, owing to genetic predisposition coupled with unhealthy lifestyle habits. Metabolic determinants account for a fraction of epidemic non-communicable disorders such as cardiovascular, hepatic, renal diseases, and cancer. A better understanding of the molecular underpinnings of these associations promises to strengthen our diagnostic and therapeutic abilities.

4. What do you think of the development of open access in the publishing field?
Open access in publishing is a potentially revolutionary innovation that may contribute to the emergence of scholars who, for various reasons, would otherwise have few chances to publish their studies and inform the progress of science. However, open access also poses challenges that need to be faced with courage, energy, and competence.

We warmly welcome Dr. Amedeo Lonardo to his new role as Editor-in-Chief, and we look forward to him leading Metabolites to many more milestones.

Metabolites Editorial Office